基于大数据的急性缺血性脑卒中患者预后预测模型构建及验证研究

注册号:

Registration number:

ChiCTR2400086724 

最近更新日期:

Date of Last Refreshed on:

2024-07-09 14:45:43 

注册时间:

Date of Registration:

2024-07-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于大数据的急性缺血性脑卒中患者预后预测模型构建及验证研究

Public title:

Construction and verification of prognosis prediction model for patients with acute ischemic stroke based on big data

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于大数据的急性缺血性脑卒中患者预后预测模型构建及验证研究

Scientific title:

Construction and verification of prognosis prediction model for patients with acute ischemic stroke based on big data

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

蒋倩 

研究负责人:

冯灵 

Applicant:

Qian Jiang 

Study leader:

Ling Feng 

申请注册联系人电话:

Applicant telephone:

+86 156 0808 8752

研究负责人电话:

Study leader's
telephone:

+86 189 8060 2079

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2192850008@qq.com

研究负责人电子邮件:

Study leader's E-mail:

fengling216@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市天府新区兴隆街道保水逸苑D区4栋2单元603号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

603 Unit 2, Building 4, District D, Baoshui Yiyuan, Xinglong Street, Tianfu New District, Chengdu, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

610000

研究负责人邮政编码:

Study leader's postcode:

610000

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital, Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024年审(1126)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee of West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-18 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Shaolin Deng

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 2654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

huaxilunli@163.com

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

经费或物资来源:

Source(s) of funding:

None

研究疾病:

急性缺血性脑卒中  

Target disease:

Acute ischemic stroke

研究疾病代码:

None

Target disease code:

None

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1)探索影响急性缺血性卒中患者预后的关键因素。 (2)基于大数据和机器学习技术,构建急性缺血性卒中患者预后预测模型。 (3)对构建的模型进行验证。  

Objectives of Study:

(1) Exploring the key factors affecting the outcome of patients with acute ischemic stroke. (2) Based on big data and machine learning techniques, the prognosis prediction model of patients with acute ischemic stroke is constructed. (3) Validation of the constructed model.

药物成份或治疗方案详述:

无 

Description for medicine or protocol of treatment in detail:

None 

纳入标准:

Inclusion criteria

排除标准:

(1)初次头颅CT等影像学检查提示颅内出血;(2)排除其他疾病引起的继发性脑卒中;(3)其他脑内功能障碍或遗传性疾病者;(4)伴有心、肺、肝、肾等重要脏器损伤者;⑤急性脑外动脉栓塞。

Exclusion criteria:

(1)The initial head CT imaging examination indicated intracranial hemorrhage; (2) excluded secondary stroke caused by other diseases; (3) other brain dysfunction or genetic diseases; (4) with heart, lung, liver, kidney and other vital organs injury; (5) acute external cerebral artery embolism.

研究实施时间:

Study execute time:

From 2024-07-01 00:00:00 To 2026-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-10 00:00:00 To 2026-07-01 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

1000

Group:

Trial group

Sample size:

干预措施:

干预措施代码:

None

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

改良Rankin量表

指标类型:

主要指标

Outcome:

Modified Rankin Scale (mRS)

Type:

Primary indicator

测量时间点:

测量方法:

电话随访

Measure time point of outcome:

Measure method:

Telephone follow-up

指标中文名:

卒中复发情况

指标类型:

次要指标

Outcome:

Recurrence of stroke

Type:

Secondary indicator

测量时间点:

测量方法:

电话随访

Measure time point of outcome:

Measure method:

Telephone follow-up

指标中文名:

再入院次数

指标类型:

次要指标

Outcome:

Number of readmissions

Type:

Secondary indicator

测量时间点:

测量方法:

电话随访

Measure time point of outcome:

Measure method:

Telephone follow-up

指标中文名:

出院后的不良事件发生情况

指标类型:

次要指标

Outcome:

Adverse events after discharge from hospital

Type:

Secondary indicator

测量时间点:

测量方法:

电话随访

Measure time point of outcome:

Measure method:

Telephone follow-up

指标中文名:

住院时间及住院费用

指标类型:

次要指标

Outcome:

Length of stay and hospitalisation costs

Type:

Secondary indicator

测量时间点:

测量方法:

二次数据分析

Measure time point of outcome:

Measure method:

Secondary data analysis

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

None

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

None

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age / years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Resman reseach manager http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

主要为病例记录表(Case Record Form, CRF),电子采集和管理系统(Electronic Data Capture, EDC)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-07-09 14:45:39